User profiles for D. Heinrich
Daniel HeinrichProfessor of Marketing and Digital Media Verified email at dfki.de Cited by 2377 |
Consumer brand relationships research: A bibliometric citation meta-analysis
M Fetscherin, D Heinrich - Journal of Business Research, 2015 - Elsevier
… impact; and quadrant D: high focus on the consumer brand relationship field and low impact.
From 97 journals in our dataset, 87 journals are in quadrants B, C, and D, meaning below …
From 97 journals in our dataset, 87 journals are in quadrants B, C, and D, meaning below …
PHA recovery from biomass
MH Madkour, D Heinrich, MA Alghamdi… - …, 2013 - ACS Publications
The recovery of polyhydroxyalkanoates (PHAs) from biomass, that is, from bacterial cells, is
one of the major obstacles in the industrial production of these polyesters. Since PHAs are …
one of the major obstacles in the industrial production of these polyesters. Since PHAs are …
[HTML][HTML] Alpha emitter radium-223 and survival in metastatic prostate cancer
C Parker, S Nilsson, D Heinrich, SI Helle… - … England Journal of …, 2013 - Mass Medical Soc
Background Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone
metastases with alpha particles. We assessed the efficacy and safety of radium-223 as …
metastases with alpha particles. We assessed the efficacy and safety of radium-223 as …
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3 …
Background Bone metastases frequently cause skeletal events in patients with metastatic
castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets …
castration-resistant prostate cancer. Radium-223 dichloride (radium-223) selectively targets …
[BOOK][B] Between Kant and Hegel: lectures on German idealism
D Henrich - 2008 - books.google.com
… either of these elements merely to hear Henrich. So encumbered, Henrich’s hopes for dialogue
were … the theory from Reinhold’s earlier edition, and has since discussed it at length in D. …
were … the theory from Reinhold’s earlier edition, and has since discussed it at length in D. …
Brand authenticity: Towards a deeper understanding of its conceptualization and measurement
…, V Schoenmüller, D Schäfer, D Heinrich - Advances in consumer …, 2012 - papers.ssrn.com
In times of increasing uncertainty, authenticity is an essential human aspiration, making it a
key issue in contemporary marketing and a major factor for brand success. By conducting a …
key issue in contemporary marketing and a major factor for brand success. By conducting a …
[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …
prostate cancer have improved outcomes, but there are still many aspects of management …
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
…, AA Azad, J Carles, AP Fay, N Matsubara, D Heinrich… - The Lancet, 2023 - thelancet.com
Background Co-inhibition of poly(ADP-ribose) polymerase (PARP) and androgen receptor
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
activity might result in antitumour efficacy irrespective of alterations in DNA damage repair …
The effects of organic labels on global, local, and private brands: More hype than substance?
HH Bauer, D Heinrich, DB Schäfer - Journal of Business Research, 2013 - Elsevier
With an ever-expanding market for diversified health food products, marketers can formulate
a unique selling proposition by differentiating their brands using organic labels issued by an …
a unique selling proposition by differentiating their brands using organic labels issued by an …
Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker
D Heinrich, Ø Bruland, TA Guise, H Suzuki… - Future …, 2018 - Future Medicine
… D Heinrich has received honoraria from Astellas, Bayer, Bristol-Myers Squibb, Janssen-Cilag
(Johnson & Johnson), and Novartis; has been a consultant for Bayer, Ipsen, and Roche; …
(Johnson & Johnson), and Novartis; has been a consultant for Bayer, Ipsen, and Roche; …